The role of exosomal PD-L1 in NSCLC immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Review uncovers exosomal PD-L1's role in immune evasion and therapeutic resistance in NSCLC, suggesting new treatment strategies.

Exosomal PD-L1 is linked to therapeutic resistance in non-small cell lung cancer (NSCLC).
Anti-PD-1 therapies have been effective in various cancers but face challenges in NSCLC.
Targeting exosome biogenesis through nSMase2 and Rab proteins may improve treatment outcomes.
This review highlights the potential of exosomal PD-L1 in advancing next-generation immunotherapy approaches.

Zhu et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark